Cargando…

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved for the treatment of BRCA-mutated breast cancer (BC), including triple-negative BC (TNBC) and ovarian cancer (OvCa). A key challenge is to identify the factors associated with PARPi resistance; although, previous studies sugges...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bustos, Matias A., Yokoe, Takamichi, Shoji, Yoshiaki, Kobayashi, Yuta, Mizuno, Shodai, Murakami, Tomohiro, Zhang, Xiaoqing, Sekhar, Sreeja C., Kim, SooMin, Ryu, Suyeon, Knarr, Matthew, Vasilev, Steven A., DiFeo, Analisa, Drapkin, Ronny, Hoon, Dave S. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626784/ https://www.ncbi.nlm.nih.gov/pubmed/37932806 http://dx.doi.org/10.1186/s13578-023-01151-y

Ejemplares similares

miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling
por: Knarr, Matthew, et al.
Publicado: (2020)

miR-181a modulates circadian rhythm in immortalized bone marrow and adipose derived stromal cells and promotes differentiation through the regulation of PER3
por: Knarr, Matthew, et al.
Publicado: (2019)

The Molecular ‘Myc-anisms’ Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics
por: McAnulty, Jessica, et al.
Publicado: (2020)

STING pathway expression in low‐grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?
por: Huvila, Jutta, et al.
Publicado: (2021)

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
por: Ding, Liya, et al.
Publicado: (2018)

UBQLN4 promotes STING proteasomal degradation during cisplatin‐induced DNA damage in triple‐negative breast cancer
por: Shoji, Yoshiaki, et al.
Publicado: (2022)

Nucleo-Cytoplasmic Localization Domains Regulate Krüppel-Like Factor 6 (KLF6) Protein Stability and Tumor Suppressor Function
por: Rodríguez, Estefanía, et al.
Publicado: (2010)

Crowdsourcing Awareness: Exploration of the Ovarian Cancer Knowledge Gap through Amazon Mechanical Turk
por: Carter, Rebecca R., et al.
Publicado: (2014)

STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
por: Pantelidou, Constantia, et al.
Publicado: (2022)

A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs
por: Belur Nagaraj, Anil, et al.
Publicado: (2019)

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
por: Wang, Qiwei, et al.
Publicado: (2022)

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition
por: Parikh, Aditya, et al.
Publicado: (2014)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Altered glutamine metabolism in platinum resistant ovarian cancer
por: Hudson, Chantelle D., et al.
Publicado: (2016)

Spatial profiling of cancer-associated fibroblasts of sporadic early onset colon cancer microenvironment
por: Furuhashi, Satoru, et al.
Publicado: (2023)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Detection of Tumor-Specific PTPmu in Gynecological Cancer and Patient Derived Xenografts
por: Vincent, Jason, et al.
Publicado: (2021)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression
por: Wang, Ying, et al.
Publicado: (2015)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance
por: Nagaraj, Anil Belur, et al.
Publicado: (2015)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
por: Ding, Xia, et al.
Publicado: (2016)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
por: Dziadkowiec, Karolina N., et al.
Publicado: (2017)

PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs
por: Sklias, Thodoris, et al.
Publicado: (2022)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
por: Du, Tingting, et al.
Publicado: (2022)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Cisplatin induces stemness in ovarian cancer
por: Wiechert, Andrew, et al.
Publicado: (2016)

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
por: Ding, Liya, et al.
Publicado: (2023)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
por: Hirotsu, Yosuke, et al.
Publicado: (2020)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
por: Li, Shan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kbclcj54nfqtgvv8jlr0qbdhsn